A Single-Arm, Multicenter, Open-Label Phase 2 Trial of Surufatinib in Patients with Unresectable or Metastatic Biliary Tract Cancer
Cancer（2021）
关键词
biliary tract cancer,efficacy,second-line treatment,surufatinib,vascular endothelial growth factor receptor (VEGFR) therapy
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要